Blossomhill Therapeutics priced a $150 million IPO to fund its macrocyclic cancer drug pipeline, including next-generation macrocyclic inhibitors targeting oncology indications such as EGFR-mutant non-small-cell lung cancer. The company upsized the offering to 9.4 million shares from earlier plans, pricing at the low end of its range. The proceeds will support continued advancement of lead macrocyclic programs designed to improve potency and selectivity by constraining molecular structure. The financing adds to a wave of newly public small biotechs aiming to build scalable oncology franchises. As with many late-cycle IPOs, Blossomhill’s debut reflects investor appetite for differentiated modalities and clear translational targets, rather than platform-only stories.